TCIM
FPRX

TIAA CREF Investment Management’s Five Prime Therapeutics, Inc. FPRX Stock Holding History

TIAA CREF Investment Management’s Portfolio FPRX Stock Details FPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		$2.78M Buy
207,152
+86,110
+71% +$982K ﹤0.01% 1814
2018
Q4 		$1.13M Buy
121,042
+53,682
+80% +$639K ﹤0.01% 2236
2018
Q3 		$938K Sell
67,360
-1,762
-3% -$26.2K ﹤0.01% 2449
2018
Q2 		$1.09M Sell
69,122
-4,148
-6% -$72.4K ﹤0.01% 2456
2018
Q1 		$1.26M Buy
73,270
+9,514
+15% +$186K ﹤0.01% 2322
2017
Q4 		$1.4M Sell
63,756
-10,378
-14% -$334K ﹤0.01% 2303
2017
Q3 		$3.03M Sell
74,134
-12,768
-15% -$401K ﹤0.01% 1923
2017
Q2 		$2.62M Sell
86,902
-45,440
-34% -$1.42M ﹤0.01% 2024
2017
Q1 		$4.78M Sell
132,342
-42,334
-24% -$1.87M ﹤0.01% 1622
2016
Q4 		$8.75M Sell
174,676
-8,606
-5% -$452K 0.01% 1207
2016
Q3 		$9.62K Sell
183,282
-587
-0.3% -$28K 0.01% 1143
2016
Q2 		$7.6M Buy
183,869
+42,002
+30% +$1.83M 0.01% 1237
2016
Q1 		$5.76M Buy
141,867
+1,871
+1% +$64.3K ﹤0.01% 1421
2015
Q4 		$5.81M Sell
139,996
-3,433
-2% -$115K ﹤0.01% 1460
2015
Q3 		$2.21M Sell
143,429
-1,914
-1% -$41.1K ﹤0.01% 2072
2015
Q2 		$3.61M Buy
145,343
+25,849
+22% +$576K ﹤0.01% 1916
2015
Q1 		$2.73M Buy
119,494
+62,654
+110% +$1.58M ﹤0.01% 2032
2014
Q4 		$1.53M Sell
56,840
-6,467
-10% -$111K ﹤0.01% 2412
2014
Q3 		$743K Sell
63,307
-1,348
-2% -$17K ﹤0.01% 2800
2014
Q2 		$1M Buy
64,655
+44,305
+218% +$635K ﹤0.01% 2725
2014
Q1 		$400K Buy
20,350
+5,200
+34% +$88.3K ﹤0.01% 3003
2013
Q4 		$254K Buy
+15,150
New +$188K ﹤0.01% 3070

Other funds holding FPRX

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

TIAA CREF Investment Management's FPRX Position: Q1 2019 in Review

TIAA CREF Investment Management increased its Five Prime Therapeutics, Inc. (FPRX) stake by 71% in Q1 2019, buying an estimated $982K and bringing the position to 207,152 shares worth $2.78M. The position accounts for ﹤0.01% of the portfolio, ranked #1814.

TIAA CREF Investment Management first reported a position in FPRX in Q4 2013 and has held it in 22 quarters since. The position peaked at $8.75M in Q4 2016. 113 funds tracked by Wall St. Rank hold FPRX as of Q1 2019.

  • TIAA CREF Investment Management held 207,152 shares of Five Prime Therapeutics, Inc. worth $2.78M as of Q1 2019.
  • TIAA CREF Investment Management bought 86,110 Five Prime Therapeutics, Inc. shares in Q1 2019, an estimated $982K.
  • Five Prime Therapeutics, Inc. made up ﹤0.01% of TIAA CREF Investment Management's portfolio in Q1 2019, its #1814 holding.
  • TIAA CREF Investment Management first reported a position in Five Prime Therapeutics, Inc. in Q4 2013 and has held it in 22 quarters since.
  • TIAA CREF Investment Management's Five Prime Therapeutics, Inc. position peaked at $8.75M in Q4 2016.
  • 113 funds tracked by Wall St. Rank held Five Prime Therapeutics, Inc. as of Q1 2019.

Based on TIAA CREF Investment Management's 13F filing for Q1 2019, filed 14 May 2019.